Journal
EUROPEAN NEUROLOGY
Volume 68, Issue 6, Pages 361-366Publisher
KARGER
DOI: 10.1159/000341380
Keywords
Cognition; Deep brain stimulation; Neuropsychological testing; Parkinson's disease; Subthalamic nucleus; Verbal fluency
Categories
Funding
- Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)
- Medtronic Iberica SA
- CIBERNED
- FIBAO
- Boehringer-Ingelheim
- Eisai
- Glaxo-SmithKline
- Italfarmaco
- Lundbeck
- Medtronic
- MSD
- Novartis
- Abbott
- UCB Pharma
Ask authors/readers for more resources
Background: Subthalamic nucleus deep brain stimulation (STN-DBS) improves motor function in selected patients with Parkinson's disease (PD) but can be associated with variable changes in cognitive functions. Methods: We studied 21 patients selected for STN-DBS and compared 6-month clinical and neuropsychological outcomes between those who underwent surgery (n = 9) and those who voluntarily refused it (n = 12). Results: Motor and quality of life outcomes were markedly superior in the STN-DBS group versus controls. A wide neuropsychological battery was administered, and the whole sample showed a statistically significant worsening in phonemic verbal fluency, time to perform the Trail Making Test part B, Digit Symbol score of WAIS-III and color-naming score of the Stroop Test. In comparison to controls, a trend to a slightly worse deterioration in phonemic verbal fluency was observed in the STN-DBS patients and was significantly correlated with reductions in the L-dopa-equivalent daily dose (r = 0.850, p = 0.007). Conclusion: Our study confirms the safety of STN-DBS from a cognitive standpoint; a reduction in verbal fluency at 6 months after surgery can also be related to PD progression and medication reduction. Copyright (C) 2012 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available